Group items tagged

Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run. The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to long waiting times and limited treatments. As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023. Reduced waiting times One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays. Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which could well lead to patients coming into harm and making a claim. Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the emergence of other health complications.

Pharmacy chain Superdrug has introduced what it asserts to be the most affordable private flu vaccinations offered on the UK high street. The vaccinations will be priced at £8.79 for 17.2 million members of its Ghada , and £16.99 for non-members. The 2023-24 vaccination service is set to become available across 150 of its stores starting from early September. Superdrug has taken this step in response to a change in NHS England's inclusion criteria, which has rendered the 12 million individuals aged 50-65 ineligible for the NHS flu vaccination service, the company said. The company is anticipating heightened demand for private flu vaccinations due to the postponed commencement of the NHS service and alterations in eligibility for free flu jabs. "Our waiting list for private flu vaccination services has already exceeded last year's figures, indicating a heightened demand this year," said Ghada Beal, Superdrug's Healthcare Director. "Providing this service at a more accessible price-point is significant, given the eligibility changes that will impact millions. Our private flu vaccination services provide a convenient means for individuals to safeguard themselves against flu and its potential complications." In May, the government's annual flu vaccination programme letter indicated that individuals aged 50 to 64 won't receive free flu vaccinations in the 2023/24 season. Moreover, the NHS plans to delay flu vaccine distribution to October, with the goal of enhancing protection for those aged 65 and older and other eligible groups during the winter months.

Private healthcare provider CityDoc has partnered with the National Pharmacy Association (NPA) in its bid to widen a "nationwide network of vaccine clinics" to increase footfall to community pharmacies that come onboard. The company says NPA member pharmacies that join the network will have their own dedicated page on the CityDoc website, while benefiting from having online marketing done on their behalf via an extensive Google AdWords campaign and local listings optimisation - all paid for by CityDoc. The participating pharmacies will also have access to their own booking system, marketing materials and access to the latest vaccine and private healthcare information. NPA member Nick Daines, who runs Lifestyle Pharmacy in Bath, said he has partnered with CityDoc for six years and seen "a significant increase in revenue from private services." He added: "The CityDoc partnership has allowed us to establish Lifestyle Pharmacy as a go-to venue for healthcare within Bath. "We have seen significantly increased footfall thanks to our partnership with CityDoc, which in turn has allowed us to grow the NHS and retail aspects of the business."

Highlighting the growing workforce challenges in the UK, a new report has indicated that nearly one in five (18 per cent) flexible health and care sector workers, engaged in agency work through private providers, might leave the sector in the next two years. With tens of thousands of flexible staff working within the sector every week, providing care for thousands of people, the report cautioned that failure to address their concerns could result in poor system performance and patient experience. The report is based on views drawn from over 10,000 flexible health and social care professionals, including a significant number of those working in pharmacy, gathered by strategic workforce partners Acacium Group. According to the report, 24 per cent of workers surveyed reported feeling overstretched by their workload, contributing to burnout and dissatisfaction. Concerns about working conditions and the level of support from management were cited as key reasons why some healthcare professionals are considering leaving the sector.

Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."

The Competition and Markets Authority (CMA) has revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of Metabolic Healthcare Ltd (Lloyds Direct). In the revocation order issued on February 12, the regulator said its decision was "based on the evidence it has received in its assessment of the Merger to date." The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023. It announced that it was considering "whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK)."

European asset management group Aurelius has completed the acquisition of McKesson UK, marking the company's fifth completed transaction in a year. McKesson UK is the parent company of a number of healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. It comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK's success has been underpinned by its strong LloydsPharmacy brand, its customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.

Walgreens Boots Alliance, the American owner of Boots UK, could risk losing billions after a private equity firm interested in buying its UK high street pharmacy chain valued the retailer at a steep discount, The Telegraph reported on Monday (April 11). "Buyout funds CVC and Bain indicated that they were willing to pay just £4bn for the business," the newspaper said, adding that "the consortium bowed out of the running" in March. The US retail giant Walgreens, which acquired Boots in 2014 for £9bn, has put a £7bn price tag on the UK pharmacy retail chain after selling its wholesale arm, Alliance Healthcare, last year. Citing city sources, the newspaper said the low valuation of the pharmacy multiple was "significant" because CVC's UK operations were led by Dominic Murphy, a Walgreens board member involved with Boots for 15 years. "He (Murphy) knows where the bodies are buried," the newspaper quoted one City source as stating. A spokesperson for Boots confirmed that CVC and Bain never lodged a formal offer for the company.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

LloydsPharmacy Clinical Homecare, a leading provider of home healthcare services in the UK, on Monday announced the appointment of Paul Adams as the company's new Chief Executive Officer (CEO). Before assuming his role at LPCH at the end of last year, Adams was leading transformation efforts at DD Group, formerly known as Dental Directory. With a career spanning over two decades, Adams has held influential positions at Diageo, Smith+Nephew, and served as a CEO for various Private Equity companies. He has also co-authored "The Little Black Book of Change." Adams will lead the LPCH's mission to pioneer the delivery of specialist clinical treatment therapies to patients, thereby enhancing patient outcomes within homecare and community settings while improving accessibility.

Jeremy Meader has resigned as managing director of Numark after five years on the job, and having lead the wider PHOENIX group's sales and marketing teams for about eight years. A press release issued on Wednesday (February 1) said Mr Meader "has decided to leave the business to pursue his career outside of the PHOENIX group", the owner of Numark. It said: "PHOENIX thanks Jeremy for his commitment and dedication over the years and wishes him all the best for his professional and private future." Previous to joining PHOENIX, Mr Meader was head of sales at Alliance Healthcare, a role he took up in 2012 after serving GSK's Consumer Healthcare division for over 13 years in various capacity.

Walgreens Boots Alliance on Tuesday (June 28) scrapped the plan to sell its UK high street pharmacy chain saying no third party was able to make an adequate offer due to the turmoil in global financial markets. Walgreens' move to call off the sale comes as private equity bidders Apollo Global and TDR faced headwinds in raising financing for the deal, as banks were wary of underwriting large chunks of the financing due to tough market conditions. Boots was initially valued at as much as £8bn with the auction process being led by Goldman Sachs. Global economic uncertainty and rising inflation have triggered a spike in interest rates as central banks have rushed to take action in the most widespread tightening of monetary policy for more than two decades, making deal financing costlier and harder to access. Walgreens had put its Boots UK business up for sale after announcing a strategic review in January as the second-largest US pharmacy chain renewed its focus on domestic healthcare. The company said the decision to retain Boots and No7 Beauty Company was also underpinned by their ongoing strong performance.

Superdrug has reported more than 400 per cent spike in sale of the chickenpox vaccines in the UK. To protect children against the disease during chickenpox season, nearly nine out of 10 patients (87 per cent) have taken their wards under the age of five for vaccination in the last eight weeks. Chickenpox can be a seasonal disease with children usually catching it in the winter and spring, with UK peaks often between March and May. The last two years of spending time in and out of various lockdowns have meant less interaction between people, and so less transmission across the general population. Caris Newson, head of healthcare services at Superdrug, said: "One of the knock-on effects of Covid is that people have a greater awareness and understanding of the benefits that vaccines can offer. "We launched the chickenpox vaccination service five years ago in 2017 and it's now that we're beginning to see greater interest in how it can support family health. In fact, our fully qualified nurses have told us that they've had more parents ask about the chickenpox vaccination service, and word of mouth has then spread amongst parents and schools."

If you're thinking of heading a startup, owning a local pharmacy could be an incredibly lucrative opportunity. When you set up a business in the healthcare sector, it's important to ensure that you operate with transparency to keep yourself and your patients safe. Whether you've acquired pharmacies before or you're turning to a new venture with different partners, learning the relevant steps before getting involved is imperative. Successful pharmacies rely on medical expertise, professional knowledge, and an excellent quality of service. Step 1: Do you need qualifications to be a pharmacist? No matter if you already have a background in pharmacy or you're entering the field from an entrepreneurial perspective, you'll need to have the right qualifications. You can become a pharmacist by completing a Master of Pharmacy degree at a university. Your chosen course needs to be approved by the General Pharmaceutical Council and will take at least four years to complete. After your degree, you'll also need to take the one-year pharmacist foundation training scheme. To access these courses, you'll usually need two or three A levels, including Chemistry. Alternatively, you could do a pharmacy foundation degree if you only have one A level or equivalent.

The International Pharmaceutical Federation (FIP) has issued a new policy statement which encourages a "life-course" approach to vaccination by pharmacists. In the statement, published on September 27, FIP backed expansion of vaccine schedules and strategies so that patients of all age groups could be vaccinated throughout their entire lifespan, from infancy to old age. A life-course approach in public health and healthcare focuses on an individual's health and well-being, including vaccination, administered throughout their entire lifespan, from infancy to old age. FIP urged governments and policymakers to eliminate regulatory barriers, enabling pharmacists to prescribe and administer all relevant vaccines throughout the life-course. Additionally, FIP recommended that policymakers develop remuneration models for pharmacies to deliver sustainable life-course vaccination services within the private and public sectors.

The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues. NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024. As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers. It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.

Community pharmacists in England have slammed the government's latest decision to reduce the number of people who get a free winter flu jab in the 2022-23 flu season, as concerns related to Covid-19 still exist. This follows a letter from the NHS England and NHS Improvement (NHSE&I) to clinicians, which stated that the flu vaccination service in 2022-23 will be offered to patient groups eligible in line with pre-pandemic recommendations. The eligibility was widened significantly after the pandemic struck in 2020 to help reduce the death toll from the Covid-19. With the change in place people aged 50-64 and schoolchildren aged 11-15 will not be eligible to receive the free jabs on the NHS next winter, pushing millions of people to pay for their jabs privately. It further recommended that vaccination for frontline healthcare workers and social care workers should be provided by employers as part of the organisation's policy to prevent the transmission of infection.